drugset / Trial / NCT01566201

Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery Disease

NCT01566201

Completed 80 enrolled University of Athens
RandomizedCrossoverTriple-blindTreatment

Summary

Inhibition of interleukin-1 (IL-1) activity in patients with RA without CAD ameliorates vascular and LV function. Moreover, data from species shows beneficial effect of this treatment on LV function after experimental myocardial infarction. The purpose of this study is to investigate whether anakinra, an IL-1 receptor antagonist, improves vascular and left ventricular (LV) function in patients with coronary artery disease (CAD) and coexistent rheumatoid arthritis (RA).

Timeline

Start
2011-03
Primary completion
2012-04
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anakinra Protein / enzyme biologic 100 mg Subcutaneous